Under-prescribing of cardiovascular therapies for diabetes in primary care

European Journal of Clinical Pharmacology

Volumn 58, Issue 12, 2003, Pages 835-841

  Bennett, K E ^a   Williams, D ^b   Feely, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Prescription databases; Primary care; Secondary preventative therapies

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC KIT; DISEASE MARKER; FEMALE; HUMAN; IRELAND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037617723     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0542-6     Document Type: Article

References (35)

1. Lowel H, Koenig W, Engel S, Horman A, Keil U (2000) The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43:218-226
2. UK Prospective Diabetes Study Group (UKPDS) (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444
4. Kannel W, D.McGee (1979) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038
5. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H (1983) Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ 287:867-870
6. Hypertension in Diabetes Study (HDS) (1993) Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11:309-317
7. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
8. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:1004-1010
9. Scandinavian Simvaststatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with CHD; the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JD, Cole TG, Brown L et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1009
11. Long-term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1357
12. Shephard J, Coble SM, Ford I, Isles CG, Lorimar AR, Mac-Farlane PW et al (1995) Prevention of coronary heart disease with prevastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307
13. Downs JR, Stein EA, Weis S, Clearfield M, Whitney E, Shapiro DR et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279:1615-1622
14. Heart Protection Study Collaborative Group (2002) MRC/ BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23-33
15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al (1998) Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762
16. Department of Health and Children (1999) Building healthier hearts: the report of the Cardiovascular Health Strategy Group. Stationary Office, Dublin
17. Feely J (1999) The therapeutic gap - compliance with medication and guidelines. Atherosclerosis 147[Suppl 1]:S31-S37
18. Irish College of General Practitioners Diabetes Task Group (2000) Guidelines for Diabetes Care in the Community. Dublin
19. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K et al (1998) Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19:1434-1503
20. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554-572
21. Feely J, Chan R, McManus J, O'Shea B (1999) The influence of Hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16:175-181
22. WHO (2001) Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). Geneva
23. McNally PG (1999) Epidemiology of heart disease in type 1 and 2 diabetes. In: McNally PG (ed) Diabetes and cardiovascular complications. Science, London
24. Cannon P, Connell P, Stockley I, Garner S (1988) Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1:979-981
25. Stata statistical software (1999) College Station, Texas
26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in patients with type 2 diabetes and in nondiabetic patients with and without prior myocardial infarction. New Engl J Med 339:229-234
27. American Diabetes Association (2001) Aspirin therapy in diabetes: position statement. Diabetes Care 24[Suppl 1]:1-4
28. Erkens JA, Stolk RP, Spolestra JA, Grobbee DE, Leufkens HGM, Klungel OH (2001) Cardiovascular drug use and Hospitilizations attributable to type 2 diabetes. Diabetes Care 24:1484-1432
29. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713-720
30. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL (1991) Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than men? The Rancho Bernado Study. JAMA 265:627-631
31. Williams D, Feely J (2001) Co-prescribing with nitrate therapies shows neglect in secondary prevention. Br J Clin Pharmacol 51:379
32. Lawrence JM, Bennett P, Young A, Robinson AM (2001) Screening for diabetes in general practice: cross sectional population study. BMJ 323:548-551
33. Barry M, Heerey A (2002) Cost-effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Ir Med J 95:133-135
34. IDF(Europe) (1999) Desktop guide to type 2 diabetes mellitus. Diabetic Med 16:730
35. IDF(Europe) (1999) Desktop guide to type 1 diabetes mellitus. Diabetes Nutr Metab 12:345-378